. Author manuscript; available in PMC: 2013 May 1.

Published in final edited form as: Drug Discov Today. 2011 Dec 20;17(9-10):514–521. doi: 10.1016/j.drudis.2011.12.013

Table 2.

Novel TB drugs in phase 2 trials that may potentially be of use in treatment of LTBI

Drug	Class	Mechanism of Action
PA-824	Nitroimidazole	• Inhibits cell wall synthesis • Toxic reactive nitrogen species released following bioreduction. • Bactericidal/Sterilizing. • Active against replicating and non-replicating bacilli
OPC-67683	Nitroimidazole	• Toxic reactive nitrogen species release following bioreduction. • Bactericidal/Sterilizing. • Active against replicating and non-replicating bacilli
TMC207	Diarylquinoline	• Inhibits mycobacterial ATP synthase • Bactericidal/Sterilizing. • Active against replicating and non-replicating bacilli